The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

International Journal of Clinical Practice

Volumn 69, Issue 10, 2015, Pages 1071-1087

  Brunton, S A ^a  

^a Primary Care Metabolic Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ANTIDIABETIC ACTIVITY; BLADDER CANCER; BODY WEIGHT; BONE DENSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; FAINTNESS; FRACTURE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; OUTCOME ASSESSMENT; PANCREAS ISLET CELL FUNCTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; TIME FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942818934     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12675     Document Type: Review

References (112)

1. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report: Estimates of diabetes and its burden in the United States, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14.htm (accessed 8 August 2014).
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37 (Suppl 1): S81-90.
3. DeFronzo RA,. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.
4. Bailey CJ, Aschner P, Del Prato S, et al., Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res 2013; 10: 397-409.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
7. Stratton IM, Adler AI, Neil HA, et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
8. Ohkubo Y, Kishikawa H, Araki E, et al., Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
9. Holman RR, Paul SK, Bethel MA, et al., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
10. Hemmingsen B, Lund SS, Gluud C, et al., Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 11: CD008143.
11. Ray KK, Seshasai SR, Wijesuriya S, et al., Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-72.
12. Turnbull FM, Abraira C, Anderson RJ, et al., Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-98.
13. Mannucci E, Monami M, Lamanna C, et al., Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604-12.
14. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl 1): S14-80.
15. Del Prato S, LaSalle J, Matthaei S, Bailey CJ,. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2010; 64: 295-304.
16. DeFronzo RA, Eldor R, Abdul-Ghani M,. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36 (Suppl 2): S127-38.
17. Bunck MC, Corner A, Eliasson B, et al., Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2041-7.
18. Bunck MC, Diamant M, Corner A, et al., One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-8.
19. Chang AM, Jakobsen G, Sturis J, et al., The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52: 1786-91.
20. Gastaldelli A, Ferrannini E, Miyazaki Y, et al., Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007; 292: E871-83.
21. Kahn SE, Haffner SM, Heise MA, et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
22. Kahn SE, Lachin JM, Zinman B, et al., Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 2011; 60: 1552-60.
23. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al., Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-54.
24. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
25. Deacon CF,. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18.
26. Mogensen CE,. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-9.
27. Rahmoune H, Thompson PW, Ward JM, et al., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-34.
28. Vestri S, Okamoto MM, de Freitas HS, et al., Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001; 182: 105-12.
29. Gerich JE,. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-42.
30. Wright EM, Loo DD, Hirayama BA,. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-94.
31. Abdul-Ghani MA, Norton L, Defronzo RA,. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32: 515-31.
32. Santer R, Kinner M, Lassen CL, et al., Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14: 2873-82.
33. Santer R, Calado J,. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-41.
34. McCrimmon RJ, Evans ML, Jacob RJ, et al., AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. Am J Physiol Endocrinol Metab 2002; 283: E1076-83.
35. Rossetti L, Smith D, Shulman GI, et al., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-5.
36. Han S, Hagan DL, Taylor JR, et al., Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
37. Sha S, Devineni D, Ghosh A, et al., Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-72.
38. Oliva RV, Bakris GL,. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014; 8: 330-9.
39. European Medicines Agency. Jardiance [summary of product characteristics] June 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002677/WC500168592.pdf (accessed 5 March 2015).
40. Boehringer Ingelheim Pharmaceuticals Inc. Jardiance (empagliflozin) tablets, for oral use [prescribing information] August 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204629s000lbl.pdf (accessed 5 March 2015).
41. AstraZeneca Pharmaceuticals LP. Farxiga (dapagliflozin) tablets, for oral use [prescribing information] August 2014. http://www.azpicentral.com/farxiga/pi-farxiga.pdf#page=1 (accessed 5 March 2015).
42. European Medicines Agency. Assessment report: Forxiga (dapagliflozin). Procedure no. EMEA/H/C/002322, 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002322/WC500136024.pdf (accessed 10 April 2014).
43. Janssen Pharmaceuticals Inc. Invokana (canagliflozin) tablets, for oral use [prescribing information] May 2014. http://www.invokanahcp.com/prescribing-information.pdf (accessed 2 March 2015).
44. European Medicines Agency. Invokana [summary of product characteristics] September 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002649/WC500156456.pdf (accessed 5 March 2015).
45. European Medicines Agency. Xigduo [summary of product characteristics] October 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002672/WC500161033.pdf (accessed 5 March 2015).
46. AstraZeneca Pharmaceuticals LP. Xigduo XR (dapagliflozin and metformin HCl extended-release) tablets, for oral use [prescribing information] October 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205649s000lbl.pdf (accessed 5 March 2015).
47. Janssen Pharmaceuticals Inc. Invokamet (canagliflozin and metformin hydrochloride) tablets, for oral use [prescribing information] August 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204353s000lbl.pdf (accessed 3 March 2015).
48. European Medicines Agency. Vokanamet [summary of product characteristics] May 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002656/WC500166670.pdf (accessed 5 March 2015).
49. Garber AJ, Abrahamson MJ, Barzilay JI, et al., American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013; 19 (Suppl 2).
50. Inzucchi SE, Bergenstal RM, Buse JB, et al., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-9.
51. Ferrannini E, Ramos SJ, Salsali A, et al., Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-24.
52. Bailey CJ, Gross JL, Pieters A, et al., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-33.
53. Henry RR, Murray AV, Marmolejo MH, et al., Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446-56.
54. Strojek K, Yoon KH, Hruba V, et al., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-38.
55. Jabbour SA, Hardy E, Sugg J, Parikh S,. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014; 37: 740-50.
56. Nauck MA, Del Prato S, Meier JJ, et al., Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-22.
57. Rosenstock J, Vico M, Wei L, et al., Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-8.
58. Wilding JP, Woo V, Soler NG, et al., Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-15.
59. Stenlof K, Cefalu WT, Kim KA, et al., Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-82.
60. Cefalu WT, Leiter LA, Yoon KH, et al., Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-50.
61. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al., Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-92.
62. Schernthaner G, Gross JL, Rosenstock J, et al., Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-15.
63. Wilding JP, Charpentier G, Hollander P, et al., Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-82.
64. Forst T, Guthrie R, Goldenberg R, et al., Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-77.
65. Matthews DR, Fulcher G, Perkovic V, et al., Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes. Diabetologia 2012; 55: S314 (Abstract 764).
66. Roden M, Weng J, Eilbracht J, et al., Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-19.
67. Häring HU, Merker L, Seewaldt-Becker E, et al., Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-9.
68. Häring HU, Merker L, Seewaldt-Becker E, et al., Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-404.
69. Kovacs CS, Seshiah V, Swallow R, et al., Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2013; 16: 147-58.
70. Kohan DE, Fioretto P, Tang W, List JF,. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962-71.
71. Yale JF, Bakris G, Cariou B, et al., Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-73.
72. Barnett AH, Mithal A, Manassie J, et al., Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 369-84.
73. Baker WL, Smyth LR, Riche DM, et al., Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-75.
74. Zhang M, Zhang L, Wu B, et al., Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2014; 30: 204-21.
75. Weir MR, Januszewicz A, Gilbert RE, et al., Lower blood pressure (BP) with canagliflozin (cana) in subjects with type 2 diabetes mellitus (T2DM). Diabetes 2013; 62 (Supplement 1): (Abstract 1077-P).
76. Hach T, Gerich J, Salsali A, et al., Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetes 2013; 62 (Supplement 1): Abstract 69-LB.
77. Tikkanen I, Narko K, Zeller C, et al., Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-8.
78. Bolinder J, Ljunggren O, Johansson L, et al., Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2013; 16: 159-69.
79. Ridderstrale M, Andersen KR, Zeller C, et al., Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700.
80. Salsali A, Bastien A, Mansfield T, et al., Dapagliflozin improves hyperglycemia and beta-cell function without increasing hypoglycemic episodes in patients with type 2 diabetes mellitus. American Association of Clinical Endocrinologists (AACE), San Diego, CA, April 13-17, 2011. Abstract 204.
81. Mudaliar S, Henry RR, Boden G, et al., Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014; 16: 137-44.
82. Wajchenberg BL,. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol 2010; 654: 515-35.
83. Mari A, Schmitz O, Gastaldelli A, et al., Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002; 283: E1159-66.
84. Ferrannini E, Muscelli E, Frascerra S, et al., Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508.
85. Merovci A, Solis-Herrera C, Daniele G, et al., Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-14.
86. Johnsson KM, Ptaszynska A, Schmitz B, et al., Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 479-84.
87. Nyirjesy P, Sobel JD, Fung A, et al., Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109-19.
88. Kim G, Gerich JE, Salsali A, et al., Empagliflozin (EMPA) increases genital infections but not urinary tract infections (UTIs) in pooled data from four pivotal phase III trials. Diabetes 2013; 62 (Supplement 1): LB21 (Abstract 74-LB).
89. Geerlings S, Fonseca V, Castro-Diaz D, et al., Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014; 103: 373-81.
90. Johnsson KM, Ptaszynska A, Schmitz B, et al., Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 473-8.
91. Nicolle LE, Capuano G, Fung A, Usiskin K,. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014; 126: 7-17.
92. Liakos A, Karagiannis T, Athanasiadou E, et al., Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 984-93.
93. US Food and Drug Administration. FDA briefing document: Invokana (canagliflozin) tablets. NDA 204042, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (accessed 10 April 2014).
94. Wanner C, Toto RD, Gerich J, et al., No increase in bone fractures with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM). J Am Soc Nephrol 2013; 24: 205A (Abstract TH-PO452).
95. Nigro SC, Riche DM, Pheng M, Baker WL,. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother 2013; 47: 1301-11.
96. Zinman B, Inzucchi SE, Lachin JM, et al., Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014; 13: 102.
97. Turner RC, Millns H, Neil HA, et al., Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-8.
98. Rodriguez-Gutierrez R, Gonzalez-Saldivar G,. Canagliflozin. Cleve Clin J Med 2014; 81: 87-8.
99. Ptaszynska A, Hardy E, Johnsson E, et al., Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 2013; 125: 181-9.
100. Basile JN,. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013; 27: 280-6.
101. Dziuba J, Alperin P, Racketa J, et al., Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 2014; 16: 628-35.
102. Kim SY, Guevara JP, Kim KM, et al., Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 170-80.
103. Kim SY, Guevara JP, Kim KM, et al., Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61: 885-92.
104. Neal B, Perkovic V, de Zeeuw D, et al., Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013; 166: 217-23 e11.
105. Center for Drug Evaluation and Research. Summary review. Invokana (canagliflozin), 2013. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204042Orig1s000SumR.pdf (accessed 29 October 2014).
106. Gilbert RE,. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int 2014; 86: 693-700.
107. Cherney DZ, Perkins BA, Soleymanlou N, et al., Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-97.
108. Cherney DZ, Perkins BA, Soleymanlou N, et al., The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
109. Perkins BA, Cherney DZI, Partridge H, et al., Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014; 37: 1480-3.
110. Henry RR, Rosenstock J, Chalamandaris AG, et al., Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study. Diabetes 2013; 62: (Abstract 70-LB).
111. Kasichayanula S, Liu X, Lacreta F, et al., Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014; 53: 17-27.
112. Lamos EM, Younk LM, Davis SN,. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013; 9: 763-75.